Literature DB >> 6967067

Secretion of the vitamin K-dependent protein of bone by rat osteosarcoma cells. Evidence for an intracellular precursor.

S K Nishimoto, P A Price.   

Abstract

Four clonal cell lines derived from a rat osteosarcoma were tested for the ability to secrete the gamma-carboxyglutamic acid-containing protein of bone (BGP) using a specific radioimmunoassay for this protein. Two cell lines secreted BGP into culture media while the other two did not. Other investigators have shown that these two cell lines are also the only ones with the high parathyroid hormone responsiveness and alkaline phosphatase activity expected for osteoblast cells in culture. Both cell lines also form a mineralized sarcoma when implanted in rats. The BGP in culture media is identical in molecular weight and in electrophoretic mobility with the 5800-dalton BGP purified from rat bone. Thus, BGP is probably secreted by osteosarcoma cells directly and not derived from an extracellular precursor by proteolytic cleavage. There are two immunoreactive components within osteosarcoma cells which secrete BGP. One component is identical in molecular weight and electrophoretic mobility with BGP from rat bone. The other component has a higher molecular mass (approximately 9000 daltons) and about half the electrophoretic mobility of BGP from bone. The presence of both components within these cells raises the possibility that the larger component may be an intracellular precursor which is processed to BGP prior to secretion.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967067

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Production of monoclonal antibodies specific for human bone gamma-carboxyglutamic acid containing protein.

Authors:  T Ohta; M Mori; H Koshiba; J Takada; T Matsuyama; S Ishii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  The effect of cyclosporin A administration on bone metabolism in the rat evaluated by biochemical markers.

Authors:  K Kawana; M Takahashi; K Kushida; H Hoshino; S Sakata; T Inoue
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

3.  Induction of matrix Gla protein synthesis during prolonged 1,25-dihydroxyvitamin D3 treatment of osteosarcoma cells.

Authors:  J D Fraser; P A Price
Journal:  Calcif Tissue Int       Date:  1990-04       Impact factor: 4.333

4.  Sex- and age-related changes in bone and serum osteocalcin.

Authors:  D Vanderschueren; G Gevers; G Raymaekers; P Devos; J Dequeker
Journal:  Calcif Tissue Int       Date:  1990-03       Impact factor: 4.333

5.  Culture and behavior of osteoblastic cells isolated from normal trabecular bone surfaces.

Authors:  P J Marie; A Lomri; A Sabbagh; M Basle
Journal:  In Vitro Cell Dev Biol       Date:  1989-04

6.  Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3.

Authors:  S A Kerner; R A Scott; J W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

7.  Immunocytochemical localization of BGP in human bones in various developmental stages and pathological conditions.

Authors:  T Ohta; M Mori; K Ogawa; T Matsuyama; S Ishii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

8.  The Walker 256/B carcinosarcoma in thyroparathyroidectomized rats: a model to evaluate inhibitors of bone resorption.

Authors:  R Rizzoli; H Fleisch
Journal:  Calcif Tissue Int       Date:  1987-10       Impact factor: 4.333

9.  Identification of the noncollagenous proteins of bovine bone by two-dimensional gel electrophoresis.

Authors:  P D Delmas; R P Tracy; B L Riggs; K G Mann
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

10.  Evaluation of the usefulness of serum phosphatases and osteocalcin as serum markers in a calcium depletion-repletion rat model.

Authors:  H Tanimoto; K H Lau; S K Nishimoto; J E Wergedal; D J Baylink
Journal:  Calcif Tissue Int       Date:  1991-02       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.